Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Malnutrition and frailty are common in chronic kidney disease (CKD) and are linked to higher mortality and progression to end-stage kidney disease. Patients with frailty often show lower treatment tolerance and are prone to adverse drug effects. This study evaluated the efficacy and safety of finerenone in diabetic CKD patients with coexisting frailty (including prefrailty) or undernutrition.
This retrospective observational study included diabetic CKD patients who initiated finerenone at our institution. Of 162 patients, 154 had sufficient eGFR data over the observation period and were included in the analysis. Frailty was defined as a Japanese Cardiovascular Health Study score ≥1, encompassing both frail and prefrail individuals. Undernutrition was defined as a Controlling Nutritional Status (CONUT) score ≥5. The primary endpoint was change in eGFR slope before and after treatment, with the post-treatment slope calculated from months 3 to 12 to minimize early-phase variability. Secondary endpoints included early eGFR decline and serum potassium changes. eGFR slopes were compared using a linear mixed-effects model.
Among 154 patients, 51 had frailty and 22 were undernourished. The overall eGFR slope improved significantly post-treatment: pre-treatment −0.58 (95% CI: −0.78 to −0.39) vs. post-treatment −0.15 (−0.24 to −0.05) mL/min/1.73 m²/month (P < 0.001). Similar improvements were observed in patients with frailty [−0.75 to −0.12, P < 0.001] and undernutrition [−0.89 to −0.35, P = 0.029]. Significant reductions in proteinuria were seen in patients without frailty or undernutrition, but not in those with either condition. At one month, early eGFR change was categorized as follows: no decline (35%), 0–10% decline (26%), >10% decline (38%). The median percentage change in eGFR did not differ significantly between patients with and without frailty [−3.6% (IQR: −11.8 to 6.3) vs. −7.1% (−15.4 to 1.6), P = 0.31], or between undernourished and others [−1.9% (−15.5 to 3.2) vs. −6.5% (−12.1 to 2.2), P = 0.97]. No significant increases in serum potassium were observed after finerenone initiation, regardless of frailty or nutritional status.
Finerenone attenuated CKD progression, including in patients with frailty or undernutrition. However, proteinuria reduction was not observed in these subgroups. Importantly, early post-treatment eGFR decline and hyperkalemia were not more frequent in frail or undernourished patients.
